Vistagen Therapeutics Inc
VTGN2.910USD
-0.010-0.34%
收盤 08/04, 16:00（美東）報價延遲15分鐘
84.38M總市值
虧損本益比TTM
關於 Vistagen Therapeutics Inc 公司
Vistagen Therapeutics, Inc. 是一家專注於神經科學的生物製藥公司。該公司基於對鼻腦神經迴路的理解，致力於開發和商業化治療精神和神經疾病的療法。其臨牀階段產品線包括一種新型潛在神經科學療法（稱爲 pherines）的鼻內產品候選物。其多樣化的 pherine 產品候選物產品線可快速激活鼻腔中的化學感應神經元，從而影響嗅覺系統和大腦中的基本神經迴路。其產品線還包括一種口服前藥，具有調節 N-甲基-D-天冬氨酸受體 (NMDA) 受體活性的潛力。其神經科學產品線包括五種臨牀階段研究藥物，即 Fasedienol (PH94B)、Itruvone (PH10)、AV-101、PH15、PH80 和 PH284。
公司簡介
公司代碼VTGN
公司名稱Vistagen Therapeutics Inc
上市日期Oct 18, 2010
CEOMr. Shawn K. Singh, J.D.
員工數量56
證券類型Ordinary Share
年結日Oct 18
公司地址343 Allerton Avenue
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94080
電話16505773600
網址https://www.vistagen.com/
公司代碼VTGN
上市日期Oct 18, 2010
CEOMr. Shawn K. Singh, J.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Shawn K. Singh, J.D.
Mr. Shawn K. Singh, J.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
38.90K
--
Dr. Jerry B. Gin, Ph.D.
Dr. Jerry B. Gin, Ph.D.
Independent Director
Independent Director
13.33K
--
Mr. Joshua S Prince
Mr. Joshua S Prince
Chief Operating Officer
Chief Operating Officer
10.86K
--
Mr. Jon S. Saxe, J.D.
Mr. Jon S. Saxe, J.D.
Independent Director
Independent Director
1.86K
--
Mr. Reid G. Adler, J.D.
Mr. Reid G. Adler, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Mary L. Rotunno
Ms. Mary L. Rotunno
Independent Director
Independent Director
--
--
Dr. Joanne Curley, Ph.D.
Dr. Joanne Curley, Ph.D.
Independent Director
Independent Director
--
--
Ms. Cynthia (Cindy) Anderson, CPA
Ms. Cynthia (Cindy) Anderson, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Ms. Elissa Cote
Ms. Elissa Cote
Chief Corporate Development Officer
Chief Corporate Development Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Shawn K. Singh, J.D.
Mr. Shawn K. Singh, J.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
38.90K
--
Dr. Jerry B. Gin, Ph.D.
Dr. Jerry B. Gin, Ph.D.
Independent Director
Independent Director
13.33K
--
Mr. Joshua S Prince
Mr. Joshua S Prince
Chief Operating Officer
Chief Operating Officer
10.86K
--
Mr. Jon S. Saxe, J.D.
Mr. Jon S. Saxe, J.D.
Independent Director
Independent Director
1.86K
--
Mr. Reid G. Adler, J.D.
Mr. Reid G. Adler, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Margaret M. (Maggie) Fitzpatrick
Ms. Margaret M. (Maggie) Fitzpatrick
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月25日 週五
更新時間: 7月25日 週五
持股股東
股東類型
持股股東
持股股東
佔比
TCG Crossover Management, LLC
8.96%
Nantahala Capital Management, LLC
6.63%
The Vanguard Group, Inc.
6.56%
StemPoint Capital LP
5.86%
Commodore Capital LP
5.27%
Other
66.71%
持股股東
持股股東
佔比
TCG Crossover Management, LLC
8.96%
Nantahala Capital Management, LLC
6.63%
The Vanguard Group, Inc.
6.56%
StemPoint Capital LP
5.86%
Commodore Capital LP
5.27%
Other
66.71%
股東類型
持股股東
佔比
Investment Advisor
25.72%
Hedge Fund
20.80%
Research Firm
3.01%
Investment Advisor/Hedge Fund
2.07%
Individual Investor
0.34%
Other
48.06%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
119
15.51M
51.95%
-4.45M
2025Q1
178
15.52M
53.23%
-4.54M
2024Q4
189
15.27M
53.10%
-1.38M
2024Q3
188
15.00M
55.60%
-3.08M
2024Q2
215
16.08M
59.60%
-5.25M
2024Q1
231
17.00M
63.09%
-4.65M
2023Q4
242
17.28M
64.17%
+1.95M
2023Q3
236
3.11M
33.43%
-2.83M
2023Q2
238
1.09M
13.89%
-3.94M
2023Q1
249
1.40M
19.25%
-3.84M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
TCG Crossover Management, LLC
2.68M
9.18%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.98M
6.79%
-3.49K
-0.18%
Mar 31, 2025
The Vanguard Group, Inc.
1.96M
6.72%
-60.18K
-2.98%
Mar 31, 2025
StemPoint Capital LP
1.75M
6%
+38.06K
+2.22%
Mar 31, 2025
Commodore Capital LP
1.57M
5.4%
--
--
Mar 31, 2025
Sphera Funds Management Ltd.
790.55K
2.71%
-18.00K
-2.23%
Mar 31, 2025
J.P. Morgan Securities LLC
750.86K
2.58%
-21.37K
-2.77%
Mar 31, 2025
Ikarian Capital LLC
601.70K
2.06%
+524.09K
+675.23%
Mar 31, 2025
Diadema Partners LP
565.98K
1.94%
+123.45K
+27.90%
Mar 31, 2025
Adar1 Capital Management LLC
420.76K
1.44%
+299.30K
+246.42%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
AdvisorShares Psychedelics ETF
4.67%
iShares Micro-Cap ETF
0.01%
iShares Neuroscience and Healthcare ETF
0%
Avantis US Small Cap Equity ETF
0%
AdvisorShares Psychedelics ETF
佔比4.67%
iShares Micro-Cap ETF
佔比0.01%
iShares Neuroscience and Healthcare ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
公告日期
類型
比率
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
Jun 06, 2023
Merger
30<1
